Selicrelumab
- Generic Name
- Selicrelumab
- Drug Type
- Biotech
- CAS Number
- 1622140-49-1
- Unique Ingredient Identifier
- 0O39RGI33V
- Background
Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 4
- Registration Number
- NCT03892525
- Locations
- 🇫🇷
APHP - Hôpital Henri Mondor, Créteil, France
🇫🇷CHU de Rennes - Hôpital Pontchaillou, Rennes, France
🇫🇷CHU de Montpellier, Montpellier, France
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT03555149
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego Medical Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 341
- Registration Number
- NCT03193190
- Locations
- 🇺🇸
Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT02760797
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇫🇷Institut Gustave Roussy; Sitep, VILLEJUIF Cedex, France
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 94
- Registration Number
- NCT02665416
- Locations
- 🇳🇱
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
🇪🇸Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT02304393
- Locations
- 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇨🇦University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
🇨🇦Jewish General Hospital / McGill University, Montreal, Quebec, Canada
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
- First Posted Date
- 2009-11-05
- Last Posted Date
- 2015-09-24
- Target Recruit Count
- 22
- Registration Number
- NCT01008527
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.